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Abstract
 
Induction of tolerance in self-reactive memory T cells is an important process in the prevention
of autoimmune responses against peripheral self-antigens in autoimmune diseases. Although
naive T cells can readily be tolerized, memory T cells are less susceptible to tolerance induc-
tion. Recently, we demonstrated that low avidity engagement of T cell receptor (TCR) by
low densities of agonist peptides induced anergy in T cell clones. Since memory T cells are
more responsive to lower antigenic stimulation, we hypothesized that a low avidity TCR en-
gagement may induce tolerance in memory T cells. We have explored two antigenic systems in
two transgenic mouse models, and have tracked specific T cells that are primed and show
memory phenotype. We demonstrate that memory CD4
 
 
 
 T cells can be rendered anergic by
presentation of low densities of agonist peptide–major histocompatibility complex complexes
in vivo. We rule out other commonly accepted mechanisms for induction of T cell tolerance
in vivo, such as deletion, ignorance, or immunosuppression. Anergy is the most likely mecha-
nism because addition of interleukin 2–reversed anergy in specific T cells. Moreover, cytotoxic
T lymphocyte antigen (CTLA)-4 plays a critical role in the induction of anergy because we ob-
served that there was increased surface expression of CTLA-4 on anergized T cells, and that in-
jection of anti–CTLA-4 blocking antibody restored anergy in vivo.
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Introduction
 
Induction of tolerance in self-reactive memory T cells is es-
sential for prevention of autoimmune responses against pe-
ripheral self-antigens in autoimmune diseases. However, al-
though naive T cells can be tolerized successfully (1, 2),
memory T cells are less susceptible to tolerance induction in
vivo (3). Differences that distinguish naive from memory T
cells may contribute to the differential susceptibility to
tolerogenic signals. For example, naive and memory CD4
 
 
 
T cells express different patterns of adhesion molecules, such
as CD44, intercellular adhesion molecule 1, LFA-1, and
CD62L, or signaling molecules such as CD45. Because of an
increased expression of adhesion receptors, memory T cells
require less costimulation than do naive cells, and are able to
respond faster and to lower densities of antigenic challenge
(3). Some differences at the levels of TCR-induced signal-
ing pathways may also contribute to a lower activation
threshold for memory cells. Specifically, stimulation through
TCR/CD3 in murine naive versus memory CD4
 
 
 
 T cells
leads to differential phosphorylation of proteins involved in
signal transduction (4). These characteristics may enable
memory T cells to respond positively to stimulation by all
APCs, including resting B cells (5). In agreement with these
findings it has been documented that lack of costimulatory
signals does not lead to tolerance in memory T cells (2).
The role of CTLA-4 in maintaining peripheral tolerance
is well established. Recently, Greenwald et al. (1) clearly
demonstrated an essential role for CTLA-4 in regulating the
induction of anergy in vivo. It is reported that CTLA-4 is
produced and stored in endosomal vesicles in activated/
memory, but not naive T cells (6). Thus, when needed,
CTLA-4 might readily be expressed on the cell surface and
act to regulate overstimulation of activated/memory T cells.
Recently, we have demonstrated that low avidity en-
gagement of T cell receptor by low densities of agonist
peptides induced anergy in T cell clones (7). Thus, we hy-
pothesized that low avidity TCR engagement may also
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drive memory T cells to a state of anergy in vivo. To test
this hypothesis, we designed two experimental systems us-
ing two transgenic (Tg)
 
*
 
 mouse models. In one, mono-
clonal 6.5 TCR Tg mice, specific for hemagglutinin
(HA)
 
110–120
 
, and in the other, HLA-DR1 Tg mice, with a
full repertoire of T cells, were tested. We observed that
presentation of low densities of agonist peptides in complex
with MHC class II induced tolerance in specific memory
CD4
 
 
 
 T cells. We demonstrated that tolerance was not due
to ignorance or active suppression/immunoregulation. Fur-
thermore, by studying specific T cells tracked by specific
mAb or peptide–MHC II oligomers, we established that
tolerance was due to anergy but not deletion. Moreover,
induction of anergy required signaling through CTLA-4.
 
Materials and Methods
 
Mice.
 
TCR Tg mice line 6.5 that expresses an 
 
 
 
/
 
 
 
 T cell re-
ceptor recognizing an I-E
 
d
 
–restricted HA
 
110–120
 
 on a B10 back-
ground was used. NonTg B10.D2 mice at 6–8 wk of age were
purchased from The Jackson Laboratory. HLA-DR1 (DR
B1
 
*
 
0101) Tg mice (Merck) at 8–10 wk of age were studied. The
chimeric HLA-DR1 molecule comprised a peptide-binding
groove derived from the human DR1 sequence and a CD4-bind-
ing domain from I-E
 
f
 
 mice. The mice were housed in The Johns
Hopkins University animal facilities under virus-free conditions.
All experiments were performed in accordance with protocols
approved by the Animal Care and Use Committee of the Johns
Hopkins University, School of Medicine.
 
Peptides.
 
The peptides, influenza virus HA
 
306–318
 
 (PKYV-
KQNTLKLAT) and HA
 
109–120
 
 (SSFERFEIFPKE), were synthe-
sized by Peptide Express. The peptides were 
 
 
 
90% pure as ana-
lyzed by reverse-phase HPLC.
 
Immunizations.
 
To determine the immunogenicity of the
HA
 
306–318
 
, HLA-DR1 Tg mice were immunized subcutaneously
at the base of the tail with 10 nmol of HA
 
306–318
 
 emulsified at a
1:1 (vol/vol) in Complete Freund’s Adjuvant (CFA; Sigma-
Aldrich). After 2, 3, 5, 7, or 12 wk, mice were injected subcuta-
neously with increasing concentrations (0–50 nmol) of HA
 
306–318
 
in Incomplete Freund’s Adjuvant (IFA; Sigma-Aldrich). 9 d after
the second injection, inguinal lymph nodes were removed and
cells were used for assays.
 
Adoptive Transfer.
 
CD41 cells (2.5 
 
 
 
 10
 
6
 
), positive for the
clonotypic TCR, prepared from pooled lymph nodes and spleens
of TCR Tg donors, were resuspended in 200 
 
 
 
l of sterile HBSS
(Life Technologies) and injected through the tail vein of B10.D2
recipient mice. 3 d after transfer, mice were immunized (subcuta-
neously) with 15 nmol of HA
 
109–120
 
 emulsified at a 1:1 (vol/ vol)
ratio with CFA. After 5 wk, recipient mice were injected with
increasing concentrations of HA
 
109–120
 
 (0–10 nmol) mixed with
IFA. 2 or 9 d after the second injection, lymph nodes were re-
moved and cells were used for assays.
 
Proliferation Assay.
 
Cells (4 
 
  
 
10
 
5
 
) were cultured in each well
of a 96-well round-bottomed plate (Becton Dickinson) with no
peptide or various concentrations of HA
 
306–318 
 
or HA
 
109–120
 
 or pu-
rified protein derivative (PPD; Connaught Laboratories Ltd.), at
37
 
 
 
C, 5% CO
 
2
 
, for 72 h in RPMI 1640 (GIBCO BRL) supple-
mented with 10% FBS (GIBCO BRL), 2 mM 
 
L
 
-glutamine
(GIBCO BRL), 10 mM Hepes (GIBCO BRL), 50 U/ml peni-
cillin/streptomycin (GIBCO BRL) and 50 mM 2-mercaptoetha-
nol (Sigma-Aldrich). Each well was then pulsed with 1 
 
 
 
Ci of
[
 
3
 
H]thymidine (Amersham Pharmacia Biotech). 18 h later, cells
were harvested with a Packard Micromate cell harvester and the
incorporated radioactivity was measured by a Packard Matrix 96
Direct b Counter.
 
Cytokine Assays.
 
IL-2 release was measured with the IL-2–
sensitive cell line CTLL-2 (American Type Culture Collec-
tion[ATCC]). Inguinal lymph node cells (4 
 
  
 
10
 
5
 
 cells per well)
were cultured with 0, 0.1, or 1 
 
 
 
M HA
 
306–318
 
 for 24 h. Cell-free
culture supernatants were then collected, stored at 
 
 
 
70
 
 
 
C, and
thawed once. CTLL-2 cells (4 
 
  
 
10
 
5 
 
cells per well) were incu-
bated at 37
 
 
 
C, with 5% CO
 
2
 
 for 24 h in RPMI 1640 with sup-
plements (10% FBS, 2 mM 
 
L
 
-glutamine, 1.5 gram per liter so-
dium bicarbonate; Sigma-Aldrich), 10 mM Hepes plus 24-h
culture supernatants, in culture wells of 96-well round-bottomed
plates. Plates were then pulsed with 1 
 
 
 
Ci of [
 
3
 
H]thymidine for
an additional 18 h, harvested, and counted. The level of IL-2 was
calibrated against a standard curve of rIL-2. Cell-free culture su-
pernatants were collected after 48 h and IFN-
 
 
 
 was measured by
ELISA for mouse IFN-
 
 
 
 using Quantikine cytokine ELISA kit
(R&D Systems) according to the manufacturer’s protocol. All as-
says were performed in triplicate.
 
Flow Cytometric Analysis.
 
Pooled lymph node and spleen cells
(10
 
6
 
) from various mice (adoptively transferred), 3 d after transfer
of cells, 2, 3, or 5 wk after immunization were preincubated with
Fc-
 
 
 
 receptor-blocking antibody 2.4G2 (HB-197, ATCC). Cells
were washed and stained with biotinylated anticlonotypic TCR
mAb (6.5, provided by H. von Boehmer, Harvard University,
Boston, MA; reference 8) and avidin-cychrome (Cyc). The fol-
lowing mAbs were used for analysis: anti–mouse CD4-FITC;
anti–mouse CD4-PE; anti–mouse CD62L-PE; anti–mouse
CD45RB-PE; anti–mouse CD69-PE; anti–mouse CD25-FITC;
and anti–mouse CD44-FITC. 48 h after the second peptide injec-
tion, 10
 
6
 
 cells of recipient mice were stained with anticlono-
typic TCR mAb-Cyc, anti–mouse CD4-FITC, and anti–mouse
CTLA-4 PE. 9 d after the second peptide injections, 5 
 
 
 
 10
 
6
 
 cells
of HLA-DR1 Tg mice were cultured either with peptide (10 
 
 
 
M)
alone or with rIL-2 (10 U/ml) for 8 d. Cells were stained with
HA-DR1-SA-PE oligomers (provided by T. Cameron and L.
Stern, MIT, Cambridge, MA) for 3.5 h at 37
 
 
 
C followed by anti–
mouse CD4-FITC or anti–mouse CD4-Cyc and anti–mouse
CTLA-4–FITC (Southern Biotechnology Associates, Inc.). All an-
tibodies were purchased from BD PharMingen. The samples were
analyzed on a FACScan™ by using CELLQuest™ software (Bec-
ton Dickinson). In each case, 5–10 
 
  
 
10
 
4
 
 events were collected.
 
In Vivo Antibody Treatments.
 
HLA-DR1 Tg mice received
intraperitoneal injections of 85 
 
 
 
g of hamster anti–mouse CTLA-4
mAb from the culture supernatant of the UC10-4F10-11 cell line
(ATCC), which was purified on a protein A column in our labo-
ratory and showed 
 
 
 
95 purity by SDS-PAGE and silver staining.
Injections were done on days 0, 1, 2, 3, 5, and 7 after the tolero-
genic injection of various doses of HA
 
306–318
 
 in IFA.
 
Mixing Experiments for Potential Presence of Immunoregulatory Cells
in Anergic Groups.
 
The regulatory capacity of anergic T cells was
analyzed in a culture
 
 
 
in vitro. Anergic cells (2 
 
 
 
 10
 
5
 
) either from
0.0005 nmol or 0.05 nmol groups were incubated with 4 
 
 
 
 10
 
5
 
responder cells from each nonanergized group of HLA-DR1 Tg
mice together with various concentrations of HA
 
306–318
 
 (0, 0.1, 1,
10 
 
 
 
M). As positive controls, responder cells (0 and 5 nmol
groups) were treated with rhTGF-
 
 
 
 (0.1, 1, 10 ng/ml; R&D
 
*
 
Abbreviations used in this paper:
 
 CFA, Complete Freund’s Adjuvant; Cyc,
cychrome; HA, hemagglutinin; IFA, Incomplete Freund’s Adjuvant; Tg,
transgenic; PPD, purified protein derivative. 
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Systems) for 48 h. Proliferative responses were examined by
[
 
3
 
H]thymidine incorporation.
 
Results
 
Acquisition of Memory Phenotype in 6.5 TCR Tg Cells.
 
The surface phenotype of naive T cells is relatively well
characterized, and they express high levels of L-selectin
(CD62L), CD45RB, and low levels of CD44. In contrast,
the surface phenotype of memory T cells has remained
controversial. It has been proposed that memory T cells ex-
press CD45RB
 
lo
 
, CD62L
 
lo
 
, and CD44
 
hi
 
. In comparison to
activated cells, memory T cells are presumed to be small
and to have low expression of activation markers such as
CD25 (IL-2R) and CD69 (9). Memory T cells migrate
from blood and spleen to lymph nodes at a low rate (10,
Figure 1. (A) Surface phenotypes of clonotypic HA-specific CD4 T cells in
naive and immunized mice: splenocytes and lymph node cells were pooled and
triple stained with anti-CD4, anticlonotypic TCR antibody (mAb 6.5), and indi-
cated antibodies. Cell size and levels of expression of CD25, CD44, CD45RB,
CD62L, and CD69 were measured by gating on the CD4  and mAb 6.5  popu-
lation. (B) Memory cells respond faster and more efficiently to lower peptide
doses than do naive cells; lymph node cells from adoptively transferred mice at 3 d
( ) and 5 wk after immunization with HA109–120 ( ) were prepared. Cells were
restimulated with various concentration of HA109–120 peptide. Proliferation assay
was performed as described in Materials and Methods. 
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11), but reintroducing antigen can accelerate their recruit-
ment back into lymph nodes (9, 11).
To trace specific T cells and to characterize their pheno-
type, we used 6.5 TCR Tg mice specific for complexes of
HA
 
109–120
 
-I-E
 
d
 
 (8). TCR Tg CD4
 
  
 
T cells were transferred
into B10.D2 recipient mice, and 3 d later (to allow for
homing of transferred cells to the lymphoid organs), recipi-
ents were immunized with 15 nmol of HA
 
109–120
 
 in CFA.
The group called “naive” did not receive any peptide.
Lymph node and spleen cells were analyzed by size and
three-color FACS
 
®
 
 for expression of CD4, clonotypic
TCR epitope, and levels of expression of memory markers.
HA
 
109–120
 
–specific CD4
 
 
 
 T cells were stained for CD44,
CD25, CD69, CD45RB, and CD62L on day 3 after trans-
fer and 2, 3, and 5 wk after immunization. As seen in Fig. 1
A, during the 5 wk after immunization the expression level
of CD44 increased, whereas levels of CD45RB, CD62L,
CD25, and CD69 decreased. Moreover, the average cell
size decreased during the 5-wk period, consistent with dis-
tinctive smaller size for memory versus activated T cells.
 
Memory T Cells Respond more efficiently to Lower Doses of
Peptide.
 
A more reliable marker for memory T cells is
their characteristic higher sensitivity to antigenic stimula-
tion compared with naive T cells (12). For further evalua-
tion of the generation of memory T cells 5 wk after immu-
nization, we compared the dose-proliferative response of
cells from adoptively transferred mice 3 d after transfer (na-
ive phenotype) and 5 wk after immunization (memory
phenotype). Fig. 1 B shows that memory T cells prolifer-
ated in response to 100-fold lower peptide concentrations
than did naive T cells.
 
Induction of Tolerance in TCR Tg Cells In Vivo.
 
The
above data strongly suggested that memory T cells devel-
oped 5 wk after immunization. Next, we examined
whether low doses of agonist peptides could induce unre-
sponsiveness in memory T cells in vivo
 
.
 
 Induction of unre-
sponsiveness occurred when low doses of peptide were ad-
ministered 5 wk after priming (Fig. 2 A). Lack of vigorous
proliferation in tolerized groups was not due to the dele-
tion of antigen-specific cells, because we detected compa-
rable percentages of CD4
 
 
 
 6.5 TCR
 
 
 
 cells in all groups
that ranged between 0.40–0.64% (0 nmol group, 0.40%;
0.5 nmol group, 0.44%; 10 nmol group, 0.64%).
 
Specificity of Tolerance Induced by Low Doses of Peptide.
 
The mycobacterium debris antigens in CFA used in the
first immunization could prime non-TCR Tg cells to re-
spond to the bacterial PPD challenge in vitro. Thus, in or-
der to control for specificity of the tolerance induced we
tested the response levels of all groups to two different
doses of PPD in vitro. The loss of proliferation of tolerized
cells to HA
 
109–120 
 
was clearly antigen specific as the prolifer-
ation to PPD was not altered significantly (Fig. 2 B).
 
Induction of Tolerance by Low Doses of HA
 
306–318 
 
Peptide in
HLA-DR1 Tg Mice.
 
The above experiments demon-
strated that tolerance can be induced among memory T
cells of a single clonal origin adoptively transferred to a syn-
genic nonTg recipient. To further establish these findings
and to test whether multiple T cell clones specific for the
same pair of peptide–MHC could also be tolerized by this
treatment, we used Tg mice that express the human class II
molecules, HLA-DR1. These Tg mice carry chimeric I-E/
DR1 molecules where the peptide-binding groove is com-
posed of HLA-DR1, but the membrane proximal domain
is murine I-E to allow undisturbed interactions with mu-
rine CD4 on T cells. Importantly, these Tg mice develop a
diverse T cell repertoire and can give rise to human DR–
restricted immune responses after challenge with peptides
that bind HLA-DR1 (13). In addition, our previous results
demonstrating that anergy can be induced in T cell clones
by low densities of peptide–MHC had used HLA-DR1 in
complex with HA
 
306–318
 
. Notably, interaction of HLA-
DR1 and HA
 
306–318 
 
peptide
 
 
 
has been well characterized
Figure 2. Induction of anergy in adoptively transferred mice with T
cells from HA109–120-specific TCR Tg donors. 3 d after adoptive transfer
mice were immunized with HA109–120 in CFA, 5 wk after they received
different doses of HA109–120 in IFA. 9 d later cells were harvested and cul-
tured with different doses of HA109–120 (A) and PPD (B) and proliferation
was measured by [3H]thymidine incorporation. Representative of five in-
dependent experiments.723 Mirshahidi et al.
Figure 3. Low densities of agonist peptide induce anergy in memory T
cells. Mice were immunized with 10 nmol of HA306–318 in CFA; mice re-
ceived a second peptide injection 2 (A), 3 (B), or 5 wk later (C) with in-
dicated doses of HA306–318 in IFA. After 9 d, draining lymph nodes were
collected and restimulated with peptide in culture. Proliferative response
was measured. The spectrum of induction of anergy by low densities of
agonist peptide spans 3–4 logs. The experiment shown represents five in-
dependent experiments and each point represents an average of five mice.
Anergized cells are unable to produce IL-2 and IFN- ; supernatants from
lymph node cell cultures stimulated with various concentration of HA306–318
were removed after 24 and 48 h of incubation and assayed by measuring
proliferation of IL-2 sensitive CTLL-2 cell line (D), and ELISA for IFN- 
(E). One out of three representative experiments is shown.724 Anergy in Peripheral Memory T Cells Is Regulated by CTLA-4
biochemically (14–16). Thus, testing HLA-DR1 mice had
multiple advantages.
To generate memory T cells, an immunogenic dose (10
nmol  15  g) of HA306–318 in CFA was injected and dif-
ferent groups of mice received a second injection of vari-
able doses of HA306–318 2, 3, or 5 wk later. We also tested 2
and 3 wk intervals because in vivo tracing of DR1/
HA306–318–specific T cells is not currently available (17, 18).
Slightly lower doses of HA306–318 were used to compensate
for the higher binding affinity of HA306–318 for DR1.
HA306–318-DR1 complex has a dissociation half-time of 6 d
at 37 C (19). Cells from the draining nodes were removed
and tested in a proliferation assay 9 d later. At short inter-
vals between CFA priming and administration of peptide in
IFA, no tolerogenic effects were observed (Fig. 3, A and
B), consistent with the later development of memory phe-
notype. When low peptide doses were administered 5 wk
after the initial priming we observed tolerance. Fig. 3 C
depicts proliferation of cells from mice tolerized by low
doses/densities of HA306–318 (0.0005–0.05 nmol) in vivo.
Cells from these groups proliferated significantly less well
than cells from other groups that had received peptide
doses  0.0005 nmol or higher than 0.05 nmol. The in
vivo doses capable of inducing unresponsiveness spanned
3–4 logs. The inverse bell-shaped pattern of unresponsive-
ness to a range of peptide doses resembled T cell clones (7),
where densities between 1–10 peptide–DR1 complexes
per APC had the greatest inhibitory effects. Similar results
were observed when the time required for induction of an-
ergy was extended to 7 and 12 wk (see Fig. 4, A and B) as a
further proof for the longevity of memory T cells and their
susceptibility to tolerance induction by low avidity stimula-
tion. Although in most experiments we have used draining
lymph nodes isolated 9 d after tolerogenic peptide injec-
tion, tolerance was established at time points tested as early
as 2 d after second peptide injection, and persisted up to
27 d, that latest time point tested (data not shown).
It has been proposed that T cell anergy is a consequence
of the inability of a T cell to produce IL-2 (20). To deter-
mine the effect of various doses of HA306–318 on IL-2 pro-
duction, culture supernatants of draining lymph node cells
were assayed for IL-2 release. Measurement of IL-2 levels
showed that cells from mice exposed to 0.0005–0.05 nmol
of HA306–318 in vivo had markedly diminished IL-2 levels
(Fig. 3 D). As shown in Fig. 3 E, production of IFN-  was
also significantly reduced in tolerized cells. The cytokine
responses were antigen specific because cells cultured with-
out peptide contained no detectable cytokines. It has been
reported that low densities of antigen (21, 22) in IFA (23)
may cause Th cells to differentiate into Th2 rather than
Th1 cells. We examined cells for Th2 cytokines such as
IL-4, IL-5, and IL-10 secretions in culture supernatants.
We also analyzed intracellular IL-4 production in all
groups. None of the assays used detected measurable levels
of IL-4, IL-5, and IL-10 in any of the groups tested (data
not shown). Furthermore, IFN-  secreted in nontolerized
groups (0, 0.5, 5 nmol) reflects their differentiation into
Th1 cells (Fig. 3 E).
Tolerance Is not due to Suppressor T Cells or Deletion. A
potential mechanism responsible for induction of tolerance
in mature peripheral T cells is immunoregulation. Two
models have been proposed to explain the effects of immu-
noregulatory T cells. One involves suppressive effects of T
cell–derived cytokines, such as IL-4, IL-10, and TGF- ,
which inhibit the activation of IL-2–producing T cells (24,
25), and the other postulates the suppressive effects based
on competition with responding cells for access to APC
surface antigens or costimulatory molecules (26). To deter-
Figure 4. Memory T cells are targets for anergy. Seven (A) or 12 wk (B) after immunization with HA306–318 in CFA, mice received a second peptide
injection as described in Materials and Methods. The proliferative response to in vitro peptide restimulation was determined by [3H]thymidine incorpo-
ration. The experiment shown represents five independent experiments and each point represents an average of five mice.725 Mirshahidi et al.
mine whether tolerance was induced by suppressor T cells
in our system, we mixed responder cells (nonanergized
groups) with cells from two anergized groups (0.0005–
0.05 nmol) in the presence of various concentrations of
HA306–318, and then tested for T cell proliferation (Fig. 5, A
and B). To control for whether the responding cells were
responsive to suppressor cytokines, responder cells (0 and 5
nmol groups) were treated with different doses of TGF- 
in vitro (Fig. 5 C). Fig. 5 shows that tolerized cells were
unable to inhibit proliferation of antigen-specific responder
T cells, although TGF-  treatment had inhibitory effects.
Apoptosis (27) and deletion (28) are well-established
mechanisms for peripheral tolerance. To determine
whether tolerance was caused by deletion of the specific T
cells, we used HA-DR1 oligomers to trace HA306–318-spe-
cific T cells in DR1 Tg lymph node cells that had been tol-
erized. Similar to other preparations of oligomeric human
class II (17), HA-DR1-SA-PE oligomer (18) failed to de-
tect specific cells directly from a pool of lymphocytes.
Nonetheless, specific cells were detectable after 8 d in cul-
ture. We followed the protocol established previously (18)
and detected specific T cells that were stained by HA-
DR1-SA-PE oligomers in all groups of mice (Fig. 6). The
percentages of positive cells were comparable in anergized
and nonanergized groups, ranging from 0.7–1.3%, indicat-
ing that they were not deleted. It has been demonstrated in
models in vitro (20) and in vivo (29) that anergic T cells are
unable to divide because they do not produce IL-2 and that
addition of exogenous IL-2 can prevent or reverse anergy
(7, 30). Upon addition of peptide and IL-2, the percentage
of positive cells in the anergized group (0.0005 nmol pep-
tide in IFA) doubled, confirming persistence of anergic
cells (Fig. 6). The background counts for unprimed naive
cells were 0.09%.
These experiments rule out suppression or deletion
as an explanation for tolerance in our system, but pro-
vide clear evidence for anergy as the most likely expla-
nation.
Figure 5. Anergic cells cannot suppress proliferation of responder cells.
Cells from nonanergized groups (responders) plus anergized groups (A)
0.0005 nmol and (B) 0.05 nmol were cultured at 2:1 ratio with various
doses of HA306–318 peptide for 72 h. (C) Responding cells (0 and 5 nmol
groups) were treated with rhTGF-  (0, 0.1, 1, 10 ng/ml) for 48 h.726 Anergy in Peripheral Memory T Cells Is Regulated by CTLA-4
Upregulation of CTLA-4 Expression by Tolerogenic Doses of
HA Peptides. A critical role for CTLA-4 in negative regu-
lation of the immune response has been established by the
findings that CTLA-4–deficient (CTLA / ) mice display a
severe lymphoproliferative disorder combined with massive
lymphocytic infiltration that leads to tissue destruction and
death of the mice at 3–4 wk of age (31, 32). T cell toler-
ance in vivo may arise from dominant engagement of B7
molecules by the CTLA-4 over CD28 and not from lack of
costimulation (33). To test possible involvement of CTLA-4
we measured levels of CTLA-4 expression in clonotypic
HA-specific CD4  T cells (6.5 , CD4 ) of draining lymph
nodes 2 d after the second peptide injections (34, 35), and
in HA306–318–specific CD4  T cells from HLA-DR1 mice,
8 d after in vitro culture in the presence of peptide. Inter-
estingly, we observed a direct correlation between the
levels of CTLA-4 expression and the induction of T cell
unresponsiveness (Fig. 7, A and B). Mice exposed to
tolerogenic dose of peptide expressed an increased level of
CTLA-4 on their T cells, whereas T cells from mock-
immunized mice and those injected with no peptide or an
immunogenic dose had comparable levels of CTLA-4.
These observations suggest that tolerance induced by low
densities of agonist peptide in vivo may occur through
CTLA-4 signaling.
Blocking CTLA-4 Prevents Induction of Tolerance by Low
Density of Agonist Peptide. To ascertain the regulatory role
of CTLA-4 in induction of tolerance in this system, HLA-
DR1 Tg mice were treated with anti–CTLA-4 mAb. Im-
Figure 6. Anergized cells are able to expand in the
presence of rIL-2. Splenocytes and lymph node cells
from anergized and nonanergized mice were cultured
without peptide, with peptide (10  M) alone or with
rIL-2 (10 U/ml) for 8 d. Cells were stained with
HA-DR1-SA-PE oligomers and anti-CD4–FITC.
Figure 7. Expression of CTLA-4 on cells exhibiting anergy. Surface ex-
pression of CTLA-4 on (A) clonotypic HA-specific CD4 cells from drain-
ing lymph nodes of adoptively transferred mice 48 h after the tolerogenic
peptide administration and (B) HA306–318–specific CD4  T cells from
HLA-DR1 mice 8 d after in vitro culture in presence of peptide as exam-
ined by anti–CTLA-4 antibody staining. Results are from one out of two
independent experiments.727 Mirshahidi et al.
munized mice were treated with multiple injections of
anti–CTLA-4 mAb (intraperitoneally) on days 0, 1, 2, 3, 5,
and 7 after injection of tolerogenic peptide. Draining
lymph nodes were removed on day 9 and cell proliferation
to in vitro peptide restimulation was tested. Fig. 8 shows
that lymph node cells from mice given a tolerogenic pep-
tide dose proliferated weakly. In contrast, cells from mice
treated with anti–CTLA-4 mAb showed a strong pro-
liferative response. Animals injected with 0 or 5 nmol of
HA306–318 in the presence or absence of anti–CTLA-4 mAb
showed similar levels of proliferation. Therefore blocking
of CTLA-4 prevents transmission of signaling required for
T cell tolerance induced by low density of agonist peptide.
These results demonstrate that induction of tolerance in
memory T cells by low density peptide presentation is ac-
complished by the expression of CTLA-4.
Discussion
Low Densities of Agonist Peptides Induce Anergy In Vivo.
We have recently described a novel mechanism for in-
duction of a long-term T cell anergy by presentation of
low densities of agonist peptide–MHC in CD4  T cell
clones. It was estimated that 1–10 agonist HA306–318 in
complex with HLA-DR1 could internalize  1,000 TCR
(7). This was in sharp contrast to altered peptide ligand ef-
fects that are generally observed upon presentation of 2–3
orders of magnitude higher densities of peptide–MHC.
The anergic cells were unable to proliferate, secretion of
IL-2 was inhibited, and secretion of IFN-  was reduced.
Nevertheless, no inhibitory effects were observed on
downregulation of TCR or upregulation of IL-2R. Such a
phenotype denotes a state of partial stimulation of T cells
similar to that defined for the effects of classic antagonist
peptides (36, 37) or TCR engagement in the absence of
signal 2 (38). In this report, we address the relationship be-
tween the density of peptide–MHC complexes and the dif-
ferential transduction of signals in T cells in vivo.
In this study, we provide evidence that low-avidity en-
gagement of T cells, by low densities of agonist peptide–
MHC, leads to the induction of T cell unresponsiveness in
the periphery in vivo. High-avidity engagement of TCR
by peptide–MHC may lead to formation of immunological
synapse (39, 40) and sustained signaling (41). One can as-
sume that low-avidity engagements might interrupt cyto-
skeletal rearrangements and full recruitment of necessary
signaling molecules to the plasma membrane, resulting in
negative signaling and T cell anergy. However, the detailed
mechanism of these events remains to be tested.
Memory T Cells as Targets for Anergy Induction by a Low
Density of Peptide. Although induction of anergy among
naive T cells has been readily generated (42, 43), induction
of anergy in memory T cells in vivo has proved to be diffi-
cult (3). Qualitative changes that distinguish memory from
naive T cells render memory T cells able to respond to an-
tigenic challenge faster and more efficiently than naive T
cells (9, 12). Multiple reasons could account for this effect:
differences in activation requirements, TCR signaling, ex-
pression of adhesion molecules (9), and dependence on co-
stimulatory signals for activation between memory and na-
ive T cells (3, 44). In addition, memory CD8 T cells have
been shown to have a distribution of Lck different from
that of naive T cells. Lck seems to be associated with CD8
in memory, but evenly distributed in naive T cells (45).
Several observations in this study support the notion that
low densities of peptide–MHC target memory T cells.
First, and most critical, is the long generation time, a mini-
mum of 5 wk (46–48), for T cells to become receptive to
anergy. Second, specific memory T cells were able to pro-
liferate at lower peptide doses than did naive cells (Fig. 1
B), consistent with the observations of Rogers et al. (12).
Third, in comparison to cells from nonimmunized mice,
primed cells expressed low levels of CD62L and CD45RB
and increased levels of CD44 (Fig. 1 A). Finally, increased
expression of CTLA-4 also correlated with induction of
anergy (Fig. 7, A and B), consistent with the finding that
memory and not naive T cells express intracellular stores of
CTLA-4 (6, 49).
It seems reasonable to assume that memory T cells
would respond to low densities of peptide–MHC because
of the specific signaling machinery that is already associated
with their membranes. For naive T cells, such low densities
of ligands might be ignored.
Previous studies on peripheral tolerance attributed the
loss of T cell function to different mechanisms (24, 50–52).
Figure 8.  Blocking of CTLA-4 engagement prevents induction of an-
ergy. HLA-DR1 Tg mice were immunized and injected with HA306–318
as described in Materials and Methods. One group of these mice was
treated (intraperitoneally) with multiple anti–CTLA-4 mAb injections on
days 0,1, 2, 3, 5, and 7 after the second peptide injection with various
doses of HA306–318.728 Anergy in Peripheral Memory T Cells Is Regulated by CTLA-4
Diminished proliferation marks the acquired state of un-
responsiveness (anergy) in our system. Lack of prolifera-
tion in cells exposed to low doses of peptide was not due
to cellular death for the following reasons: first, antigen-
specific T cells were detectable in lymph node cells of an-
ergized mice (Figs. 6 and 7); second, anti–CTLA-4 treat-
ment restored vigorous proliferation of anergized cells
(Fig. 8); and third, anergized HA-specific CD4  T cells
from HLA-DR1 Tg mice proliferated in the presence of
rIL-2 (Fig. 6). Our conclusions are supported by reports
demonstrating that CTLA-4 ligation does not induce
apoptosis (53, 54) and that memory T cells are more resis-
tant to apoptosis (44, 55).
Recent reports suggest a role for immunoregulatory
CD25 CD4  T cells in the control of tolerance (56). Im-
munoregulatory T cells are present in the subpopulation
of CD4  cells that express activation/memory markers
CD25 CD45RBlow (57). Another report suggests that the
CD4 CD25  population contains a significant proportion
of cells with a naive/resting phenotype (58) that seem to
express CTLA-4 constitutively and to suppress the activa-
tion and proliferation of other T cells, by competing for
costimulatory molecules (59) or by triggering TGF-  se-
cretion (60). Nevertheless, cells rendered anergic by low
densities of antigen did not show any suppressive function:
they did not cause neither specific inhibition of responder
T cell proliferation (Fig. 5, A and B) nor did they induce a
general suppression in response to PPD (Fig. 2 B).
Lack of proliferation and production of IL-2 and IFN- 
in anergized groups is less likely to be due to a Th2 switch.
Two important observations support this notion: first, that
no IL-4, IL-5, or IL-10 production was detected; and sec-
ond, CTLA-4 expression, which was upregulated in the an-
ergized group, is reported to limit Th2 differentiation (61).
Finally, ignorance has been evoked as a mechanism for T
cell tolerance (62). The tolerance described here cannot be
explained by ignorance because tolerized cells had to be
primed and responded fully to the peptide challenge in the
absence of a second low dose treatment. Thus, taken to-
gether, T cell anergy best describes our findings.
Multiple reports indicate that resting B cells may be the
predominant APCs that induce tolerance. The tolerogenic-
ity of resting B cells may be due to the absence of costimu-
latory molecules such as B7, which is highly expressed in
DCs and activated B cells (63). It has been shown, however,
that both activated and resting B cells can induce tolerance
in naive but not memory T cells (2), which may be due to
less stringent requirement of memory T cells for costimula-
tory molecules. All APCs, including resting B cells can stim-
ulate memory T cells (5). Although a role for DCs as the
most potent antigen presenters has well been documented,
its role as a tolerogen is less clear. However, under the ex-
perimental conditions used here, it is likely that DCs that
express high levels of MHC class II, may preferentially bind
peptides offered at the tolerogenic, lower doses. At higher
peptide doses all APCs might access and present antigenic pep-
tides. Notably, some MHC class II expressed on DCs are
shown to be empty (64), which provokes the thought of a
new role for DCs as inducers of tolerance in peripheral T
cells (65). Studies on the way address these issues.
Use of two different Tg mouse models provides clear ev-
idence that a monoclonal 6.5  TCR Tg mice or multi-
clonal T cell populations specific for HA306–318 in HLA-
DR1 Tg mice, can be rendered tolerant. Other reports
have also investigated differences in a similar Tg system,
documenting that in the non-TCR Tg mouse model, T
cell clones of different affinities for a given peptide–MHC
complex can be stimulated or tolerized (66).
CTLA-4 Mediates Anergy. Manifestation of anergy in
this system correlates with the upregulation of CTLA-4
which can be inhibited by administration of anti–CTLA-4
mAb in vivo. Several groups have proposed that induction
of peripheral T cell tolerance is a direct consequence of
CTLA-4 engagement by B7 (33, 67). CTLA-4 can inhibit
T cell responses extracellularly, by competing for B7
ligands (68), or intracellularly, by recruiting src homology 2
domain–containing protein tyrosin phosphatase (SHP)-2
and inhibiting tyrosine phosphorylation (69), by triggering
TGF-  production (70), or by blocking cell cycle progres-
sion at the late G1 to S phase (1). Alternatively, full inhibi-
tory function of CTLA-4 may require both extra and intra-
cellular domains (71). We observed an increased level of
CTLA-4 in cells that exhibited anergy compared with
other groups of cells that received doses below or above the
tolerogenic dose of peptide (Fig. 7). Strong evidence for
the role of CTLA-4 in the induction of anergy is provided
in Fig. 8, in which enhanced T cell proliferation of the an-
ergized cells of mice that were treated with anti–CTLA-4
blocking antibody is observed. Lack of any measurable ef-
fect on proliferation of cells from other groups that did not
express CTLA-4 indicates the specific and controlled ef-
fects of anti–CTLA-4 antibody. In most reports an increase
in proliferation correlates with parallel increase in IL-2 and
IFN-  secretion (1, 33, 61, 72, 73). However, it is of inter-
est to consider the possibility that CTLA-4 blockade may
affect the sensitivity of T cells to TCR ligand and possible
effects on the proportion of cytokine-producing cells in fa-
vor of specific cytokines (74). Future experiments will ad-
dress these issues.
Immediate implications of T cell anergy by a low density
of agonist peptide–MHC include autoimmunity and viral
and tumor surveillance. Memory T cells, specific for self,
might need to be kept tolerized by encountering low den-
sities of peptide–MHC, which could be an important pro-
cess in the prevention of organ-specific autoimmune dis-
eases. Furthermore, understanding of T cell responses to
presentation of low densities of agonist peptide–MHC in
vivo is of great significance because of its pertinence in viral
infections and in antitumor responses. Many viruses and
several tumors are known to decrease expression of cell
surface MHC class II (75). Alternatively, some tumor-asso-
ciated peptides bind MHC poorly (76). The reduced sur-
face expression of MHC and low affinity peptide–MHC
complexes lead to presentation of low densities of specific
peptide–MHC, which will induce anergy to the viral pep-
tides or to tumor antigens through a CTLA-4–dependent729 Mirshahidi et al.
mechanism. A recent report demonstrating that CTLA-4
blockade reverses CD8  T cell tolerance to tumor by a
CD4  T cell– and IL-2–dependent mechanism supports
this notion (77). Thus, our findings demand a revision in
design of strategies to overcome viral infections or tumor
therapy. Rather than enhancing antigen presentation, one
may have to focus on the reversal of anergy.
In conclusion, our results strongly suggest that low den-
sities of agonist peptide induce anergy in memory T cells
and that CTLA-4 is the dominant regulatory mechanism.
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